GSK, Sino Biopharmaceutical Unit Expand Collaboration to Cover Two GSK Respiratory Therapies
MT Newswires Live
Jul 08
GSK (GSK) agreed to expand its exclusive strategic collaboration with Sino Biopharmaceutical's Chia Tai Tianqing Pharmaceutical Group subsidiary to include rights to commercialize two GSK respiratory therapies in mainland China, Sino said in a Wednesday filing.
Under the deal, Chia Tai Tianqing Pharmaceutical will secure the commercialization rights to GSK's Trelegy Ellipta and Anoro Ellipta in mainland China, according to the filing. Financial details were not disclosed.
The Sino unit will work with GSK to ensure smooth product rollout in China, covering supply, commercialization and regulatory compliance, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.